A New Murine Model for MPN: Pathololgy and Therapy of NF-E2 Overexpression

MPN 的新小鼠模型:NF-E2 过度表达的病理学和治疗

基本信息

项目摘要

Despite recent advances in our understanding of the development of Myeloproliferative Neoplasms (MPNs), the pathophysiology of these disorders remains poorly understood. Especially the predisposition of MPN patients to transform to acute leukemia is not elucidated. Based on our observation that the transcription factor nuclear factor erythroid 2 (NF-E2) is overexpressed in the majority of MPN patients, we have established a murine model for MPNs, by overexpressing NF-E2 in vivo. Besides the JAK2 V617F and c-MpI W515X mouse models, this is the only murine model of MPN that employs a molecular aberration observed in MPN patients. NF-E2 was overexpressed in all hematopoietic lineages including hematopoietic progenitor cells. Two independently generated founder lines show a phenotype with many features of MPNsj including thrombocytosis, splenomegaly and MPN-like changes in bone marrow (BM) histology. The number of BM erythroid, myeloid and megakaryocytic precursors are significantly increased in NF-E2 transgenic (tg) mice, notably the number of autonomous, EPO-independent erythroid colonies. EPO-independent colonies are a pathognomonic hallmark of MPN patients. NF-E2 transgenic mice display significantly increased mortality with autopsy findings resembling those of MPN patients including splanchnic thrombosis and bleeding diatheses. At 20 months of age, one mouse (7.6%) developed acute leukemia. Our murine model therefore displays a phenotype closely resembling many features of MPN. In addition, our preliminary data indicate that NF-E2 overexpression may predispose to the development of acute leukemia. Based on this data, we formulate the following hypotheses: Hypothesis 1: NF-E2 overexpression alters hematopoietic stem cells (HSCs) resulting in the development of an MPN phenotype. NF-E2 overexpression causes cellautonomous changes in HSCs, the phenotype is therefore transplantable and constitutes a hematopoietic stem cell disorder. Specific Aim 1: To perform primary and secondary transplants and to characterize the stem cell compartment of NF-E2 transgenic donor and recipient mice. Hypothesis 2: NF-E2 overexpression constitutes a pre-leukemic state and predisposes to the evolution to acute leukemia. Specific Aim 2: To treat NF-E2 transgenic and control mice with the mutagen N-ethyl-N-nitrosourea ENU and observe the frequency of leukemic transformation. Hypothesis 3: The pathophysiological changes evoked by NF-E2 overexpression are treatable by pharmacologic intervention. Specific Aim 3: To treat NF-E2 transgenic mice with pharmacological agents currently in pre-clinical or phase I clinical trials for MPN patients.
尽管我们对骨髓增生性肿瘤(MPN)的发展有了新的认识,但这些疾病的病理生理学仍然知之甚少。特别是MPN患者转化为急性白血病的易感性尚未阐明。基于我们观察到转录因子核因子红细胞2(NF-E2)在大多数MPN患者中过表达,我们通过体内过表达NF-E2建立了MPN的鼠模型。除了JAK 2 V617 F和c-MpI W515 X小鼠模型之外,这是唯一一种采用在MPN患者中观察到的分子畸变的MPN鼠模型。NF-E2在包括造血祖细胞在内的所有造血谱系中过表达。两个独立产生的建立者系显示具有MPNs的许多特征的表型,包括血小板增多、脾肿大和骨髓(BM)组织学中的MPN样变化。在NF-E2转基因(tg)小鼠中,BM红细胞、髓细胞和巨核细胞前体细胞的数量显著增加,特别是自主的、EPO非依赖性红细胞集落的数量。EPO非依赖性集落是MPN患者的特征性标志。NF-E2转基因小鼠的死亡率显着增加,尸检结果类似于MPN患者,包括内脏血栓形成和出血素质。在20个月大时,一只小鼠(7.6%)发生急性白血病。因此,我们的小鼠模型显示出与MPN的许多特征非常相似的表型。此外,我们的初步数据表明,NF-E2过表达可能易患急性白血病的发展。基于这些数据,我们提出了以下假设:假设1:NF-E2过表达改变造血干细胞(HSC),导致MPN表型的发展。NF-E2过表达导致HSC中的细胞凋亡变化,因此表型是可移植的并且构成造血干细胞病症。具体目标1:进行初次和二次移植,并表征NF-E2转基因供体和受体小鼠的干细胞区室。假设2:NF-E2过表达构成白血病前状态,并易于演变为急性白血病。具体目标二:用诱变剂N-乙基-N-亚硝基脲ENU处理NF-E2转基因小鼠和对照小鼠,观察白血病转化率。假设3:由NF-E2过度表达引起的病理生理变化可通过药物干预治疗。具体 目的3:用目前处于临床前或I期临床试验的药物治疗MPN患者的NF-E2转基因小鼠。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Heike L Pahl其他文献

Activators and target genes of Rel/NF-κB transcription factors
Rel/NF-κB 转录因子的激活因子和靶基因
  • DOI:
    10.1038/sj.onc.1203239
  • 发表时间:
    1999-11-22
  • 期刊:
  • 影响因子:
    7.300
  • 作者:
    Heike L Pahl
  • 通讯作者:
    Heike L Pahl
Sentinel mutations: the roses in the vineyard.
哨兵突变:葡萄园里的玫瑰。
  • DOI:
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    20.3
  • 作者:
    Heike L Pahl
  • 通讯作者:
    Heike L Pahl

Heike L Pahl的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Heike L Pahl', 18)}}的其他基金

A New Murine Model for MPN: Pathololgy and Therapy of NF-E2 Overexpression
MPN 的新小鼠模型:NF-E2 过度表达的病理学和治疗
  • 批准号:
    8533749
  • 财政年份:
    2006
  • 资助金额:
    $ 38.38万
  • 项目类别:
A New Murine Model for MPN: Pathololgy and Therapy of NF-E2 Overexpression
MPN 的新小鼠模型:NF-E2 过度表达的病理学和治疗
  • 批准号:
    8722847
  • 财政年份:
    2006
  • 资助金额:
    $ 38.38万
  • 项目类别:
A New Murine Model for MPN: Pathololgy and Therapy of NF-E2 Overexpression
MPN 的新小鼠模型:NF-E2 过度表达的病理学和治疗
  • 批准号:
    8064159
  • 财政年份:
    2006
  • 资助金额:
    $ 38.38万
  • 项目类别:
Mechanisms and effects of NF-E2 and PRV-1 overexpression in PV: Role of Jak2V617F
NF-E2 和 PRV-1 在 PV 中过表达的机制和影响:Jak2V617F 的作用
  • 批准号:
    7912878
  • 财政年份:
  • 资助金额:
    $ 38.38万
  • 项目类别:
Mechanisms and effects of NF-E2 and PRV-1 overexpression in PV: Role of Jak2V617F
NF-E2 和 PRV-1 在 PV 中过表达的机制和影响:Jak2V617F 的作用
  • 批准号:
    7691286
  • 财政年份:
  • 资助金额:
    $ 38.38万
  • 项目类别:

相似海外基金

Targeting Menin in Acute Leukemia with Upregulated HOX Genes
通过上调 HOX 基因靶向急性白血病中的 Menin
  • 批准号:
    10655162
  • 财政年份:
    2023
  • 资助金额:
    $ 38.38万
  • 项目类别:
Rapid Acute Leukemia Genomic Profiling with CRISPR enrichment and Real-time long-read sequencing
利用 CRISPR 富集和实时长读长测序进行快速急性白血病基因组分析
  • 批准号:
    10651543
  • 财政年份:
    2023
  • 资助金额:
    $ 38.38万
  • 项目类别:
Experimental and preclinical modeling of NUP98-rearranged acute leukemia
NUP98重排急性白血病的实验和临床前模型
  • 批准号:
    10829603
  • 财政年份:
    2023
  • 资助金额:
    $ 38.38万
  • 项目类别:
Rapid Acute Leukemia Genomic Profiling with CRISPR enrichment and Real-time long-read sequencing
利用 CRISPR 富集和实时长读长测序进行快速急性白血病基因组分析
  • 批准号:
    10839678
  • 财政年份:
    2023
  • 资助金额:
    $ 38.38万
  • 项目类别:
A Systems Epidemiology Approach for Predicting Methotrexate Neurotoxicity in Pediatric Acute Leukemia
预测儿童急性白血病甲氨蝶呤神经毒性的系统流行病学方法
  • 批准号:
    10655716
  • 财政年份:
    2023
  • 资助金额:
    $ 38.38万
  • 项目类别:
Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Leukemia
抗CD25放射免疫治疗和全骨髓照射治疗复发难治性急性白血病
  • 批准号:
    10435886
  • 财政年份:
    2022
  • 资助金额:
    $ 38.38万
  • 项目类别:
mRNA stability and its impact on hematopoiesis and acute leukemia
mRNA稳定性及其对造血和急性白血病的影响
  • 批准号:
    10339742
  • 财政年份:
    2022
  • 资助金额:
    $ 38.38万
  • 项目类别:
Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention
通过多层次干预使急性白血病临床试验招募多样化
  • 批准号:
    10505579
  • 财政年份:
    2022
  • 资助金额:
    $ 38.38万
  • 项目类别:
Clonal dynamics and chemoresistance mechanisms of minimal residual disease in acute leukemia
急性白血病微小残留病的克隆动力学和化疗耐药机制
  • 批准号:
    10351765
  • 财政年份:
    2022
  • 资助金额:
    $ 38.38万
  • 项目类别:
Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Leukemia
抗CD25放射免疫治疗和全骨髓照射治疗复发难治性急性白血病
  • 批准号:
    10576955
  • 财政年份:
    2022
  • 资助金额:
    $ 38.38万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了